Hyperthermia and PARP-1 inhibition in recurrent head&neck or bladder cancer
Recruiting
- Conditions
- recurrent squamous cell carcinoma of the head and neck in previously irradiated area or primary irresectable stage T4 bladder cancer (urothelial carcinoma or squamous cell carcinoma) or a local recurrent bladder cancer after radical cystectomy unfit for or who progressed after platinum-based chemotherapy and for whom no other treatments
- Registration Number
- NL-OMON28959
- Lead Sponsor
- Erasmus University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 8
Inclusion Criteria
•Recurrent squamous cell carcinoma of the head and neck in previously irradiated area or primary irresectable stage T4 bladder cancer (urothelial carcinoma or squamous cell carcinoma) or a local recurrent bladder cancer after radical cystectomy in patients unfit for or who progressed after platinum-based chemotherapy and for whom no other treatments are available.
•Age > 18 years
Exclusion Criteria
•Curative treatment options available
•Treatment according to guideline available
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recommended phase II dose of olaparib combined with hyperthermi
- Secondary Outcome Measures
Name Time Method toxicities according to CTCAE version 4.0<br>translational